Mavyret (glecaprevir/pibrentasvir) / Enanta Pharma, AbbVie  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
NCT02296905: Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

Completed
1
24
US, RoW
ABT-493, ABT-530
AbbVie
Hepatic Impairment
09/15
09/15
NCT02442258: Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function

Completed
1
46
US, RoW
ABT-493, ABT-530
AbbVie
Renal Impairment
12/15
12/15
2019-003736-22: Bioavailability and Food Effect of Experimental Glecaprevir + Pibrentasvir Pediatric Formulation in Healthy Adult Subjects

 
1
39
US
Glecaprevir 100mg / Pibrentasvir 40mg, Glecaprevir 50mg / Pibrentasvir 20mg, Film-coated tablet, Granules
AbbVie Inc., AbbVie Inc.
Hepatitis C virus (HCV) infection, HCV, Diseases [C] - Virus Diseases [C02]
 
 
NCT04682509: A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation

Completed
1
20
US
Glecaprevir/pibrentasvir, Mavyret
NYU Langone Health
ESRD
05/23
02/24

Download Options